Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321234 | 0.83 | BCL2L1 (0.74) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL31356465 | 0.83 | BCL2L1 (0.74) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL7209477 | 0.83 | BCL2L1 (0.74) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL93858 | 0.82 | BCL2L1 (1.00) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5355955 | 0.82 | BCL2L1 (0.71) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL29438783 | 0.82 | BCL2L1 (1.00) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL11269271 | 0.80 | BCL2L1 (0.64) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL16599119 | 0.80 | BCL2L1 (0.69) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL826496 | 0.80 | BCL2L1 (0.69) | BCL2L1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL19880937 | 0.80 | BCL2L1 (0.69) | BCL2L1HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017060287-A1 | PROCESS FOR THE PREPARATION OF ENCENICLINE FROM 7-CHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID CHLORIDE AND (R)-QUINUCLIDIN-3-AMINE IN THE PRESENCE OF IMIDAZOLE | SANDOZ AG (CH) | 2017-04-13 | — | — | WO | claimed |
| CN-121130933-A | Preparation method and application of lignin-derived carbon-modified carbon nitride catalyst | 福建农林大学 | 2025-12-16 | — | — | CN | disclosed |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2025-08-07 | — | — | US | disclosed |
| CN-113631536-B | Fluorene derivative and use thereof | 日产化学株式会社 | 2025-06-10 | — | — | CN | disclosed |
| CN-119409634-A | HSA fluorescent probe and synthesis and application thereof | 河北大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-119241520-A | Oxime ester photoinitiator and photopolymerization composition | 武汉尚赛光电科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118715206-A | Novel HDAC inhibitors and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-08-22 | — | — | US | disclosed |
| CN-116253676-B | Amide compound, polymer film containing amide compound, and preparation method and application of polymer film | 中国科学院理化技术研究所 | 2024-07-12 | — | — | CN | disclosed |
| US-5089489-A | Enzyme inhibitors | FARMITALIA CARLO ERBA S.R.L. (IT) | 1992-02-18 | — | — | US | disclosed |
| EP-0243173-B1 | NEW DIPHOSPHONIC ACID COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-06-26 | — | — | EP | disclosed |
| US-4963536-A | INHIBIT BONE RESORPTION | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
| US-4954493-A | ENZYME INHIBITORS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-09-04 | — | — | US | disclosed |
| EP-0187487-B1 | BENZOTHIOPHENES AND BENZOFURANS HAVING ANTIALLERGIC ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1990-08-29 | — | — | EP | disclosed |
| US-4857513-A | Diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISIWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0243173-A2 | New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | disclosed |
| US-4703053-A | Benzothiophenes and benzofurans and antiallergic use thereof | WARNER-LAMBERT COMPANY (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0187487-A1 | Benzothiophenes and benzofurans having antiallergic activity | WARNER-LAMBERT COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4514399-A | N-N'substituted polymethylene diamines | ADIR (FR) | 1985-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | BCL2L1 1435/4885HDAC1 2929/4885HDAC3 3144/4885 |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | BCL2L1 1435/4885HDAC1 2929/4885HDAC3 3144/4885 |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | BCL2L1 1435/4885HDAC1 2929/4885HDAC3 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.